This is news, reported from the sources linked below. Details can change as a story develops; updates and corrections are dated on the story. Full notice.
Vaccines Made for Congo's Ebola Strain Could Start Trials Next Week
WHO chief Tedros told the Ebola emergency committee that cases have more than doubled in three months, with 400 to 500 new cases a week, and that insecurity is now one of the biggest obstacles.
"We expect two candidate vaccines developed specifically for Bundibugyo virus to begin testing as early as next week," World Health Organization Director-General Tedros Adhanom Ghebreyesus said Tuesday, according to AFP. The candidates are a ChAdOx1 vaccine from the University of Oxford and Moderna's mRNA-1469; a WHO official said Phase 2 trials are scheduled for Nov. 26 or 27 in Bunia, Ituri province. No vaccine or treatment is approved for the Bundibugyo strain. A trial of Ervebo, a vaccine approved for the Zaire strain, began Oct. 23 and has enrolled more than 140 people.
Opening the third meeting of the WHO's emergency committee on the outbreak, Tedros said cases had more than doubled since it last met three months ago, to more than 11,000 cases and 5,400 deaths in 67 health zones across eight provinces. Children make up more than a quarter of confirmed cases and a third of deaths, and two-thirds of confirmed deaths occur outside treatment centers, a sign that infections are found too late. AFP, citing the WHO, put the count in Congo at 11,376 confirmed cases and 5,568 confirmed deaths.
Tedros said rapid spread has been halted in most of the early epicenters and that testing laboratories have grown from two to more than two dozen. But he called insecurity one of the greatest obstacles, citing an attack on Cantine-Aloya that killed 66 civilians, including three health workers, and caused more than 1,000 contacts to be lost to follow-up. In Kenya, the last of nine patients has been discharged, starting a 42-day countdown. He urged countries to drop blanket travel restrictions: "Targeted, evidence-based measures work better."
Sources